Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

5.8K
Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

p21-Activated Kinase (PAK) Group I-Targeting Inhibitors Promote the Dimeric Conformation in Live Cells.

ACS chemical biology·2026
Same author

Small-molecule modulators of HIPK4 activity and proteostasis.

bioRxiv : the preprint server for biology·2026
Same author

Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors.

Nature communications·2026
Same author

Macrocyclization of Broad-Spectrum Kinase Inhibitor Bosutinib leads to Potent and Selective Quinoline-based HIPK4 Inhibitor AZ137.

bioRxiv : the preprint server for biology·2026
Same author

Structure Merging Approach Leads to New Dual Potent and Selective USP25/USP28 Inhibitors.

Journal of medicinal chemistry·2026
Same author

Advances in BRET probes for intracellular target engagement studies.

Nature chemical biology·2026

Related Experiment Video

Updated: Aug 10, 2025

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

960

Toward effective Atg8-based ATTECs: Approaches and perspectives.

Martin P Schwalm1,2, Stefan Knapp1,2, Vladimir V Rogov1,2

  • 1Department of Biochemistry, Chemistry and Pharmacy, Institute for Pharmaceutical Chemistry, Goethe University, Frankfurt, Germany.

Journal of Cellular Biochemistry
|February 13, 2023
PubMed
Summary
This summary is machine-generated.

Developing novel targeted protein degradation requires potent ligands for Atg8-family proteins (LC3/GABARAP). Despite extensive research, no effective inhibitors have been found, hindering therapeutic applications.

Keywords:
ATTECAtg8 family proteinsGABARAPLC3autophagyinhibitorstargeted protein degradation

More Related Videos

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

3.7K
ATAC-Seq Optimization for Cancer Epigenetics Research
07:13

ATAC-Seq Optimization for Cancer Epigenetics Research

Published on: June 30, 2022

4.4K

Related Experiment Videos

Last Updated: Aug 10, 2025

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

960
Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

3.7K
ATAC-Seq Optimization for Cancer Epigenetics Research
07:13

ATAC-Seq Optimization for Cancer Epigenetics Research

Published on: June 30, 2022

4.4K

Area of Science:

  • Molecular Biology
  • Drug Discovery
  • Biochemistry

Background:

  • Targeted protein degradation is a promising therapeutic strategy.
  • Atg8-family proteins (LC3/GABARAP) mediate key cellular processes.
  • Proximity-inducing small molecules can target protein interactions.

Purpose of the Study:

  • To analyze past attempts at identifying LC3/GABARAP inhibitors.
  • To explain the lack of potent inhibitors.
  • To propose future directions for discovering selective LC3/GABARAP inhibitors.

Main Methods:

  • Literature review of reported inhibitor screening campaigns.
  • Analysis of challenges in targeting LC3/GABARAP interactions.
  • Discussion of potential strategies for inhibitor development.

Main Results:

  • Intensive screening over five years has failed to yield potent LC3/GABARAP ligands.
  • Existing approaches have been insufficient for therapeutic exploitation.
  • The lack of potent inhibitors remains a significant hurdle.

Conclusions:

  • Novel strategies are needed to identify potent and selective LC3/GABARAP inhibitors.
  • Further research could unlock therapeutic applications for targeted protein degradation.
  • Understanding LC3/GABARAP interactions is crucial for drug development.